AtriCure Appoints Robert S. White to its Board of Directors

  AtriCure Appoints Robert S. White to its Board of Directors

Business Wire

WEST CHESTER, Ohio -- March 11, 2013

AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in
cardiac surgical ablation systems for the treatment of atrial fibrillation, or
AF, and systems for the exclusion of the left atrial appendage, today
announced that Robert “Bob” S. White has been appointed to the Company’s Board
of Directors, effective immediately.

Mr. White is a veteran in the medical technology industry with over 25 years
of experience in commercial expansion, operations and sales. He is currently
President and CEO of TYRX, a privately-held company, which commercializes
innovative, implantable combination drug and device products focused on
infection control, including the AIGISRx® Antibacterial Envelope, designed to
reduce surgical site infections associated with Cardiac Implantable Electronic
Devices (CIEDs). Prior to joining TYRX, Mr. White held several positions with
Medtronic, Inc. Mr. White served as President of Medtronic Kyphon following
its $3.9 billion acquisition of the spinal treatment business. During his time
with Medtronic, Mr. White also served as President of Physio Control and was
responsible for commercial operations of the Cardiac Rhythm Disease Management
business as Vice President of U.S. Sales and Global Marketing. Earlier in his
career, Mr. White held positions with General Electric Company and Eli Lilly
and Company among others. Mr. White holds a MBA from Cornell University and a
BS in Aerospace Engineering from the University of Missouri-Rolla.

"Bob has significant leadership experience spanning operations, business
development and sales and marketing within the medical device industry, and I
believe he will bring significant value to AtriCure and its Board of
Directors," said Michael Carrel, President and CEO of AtriCure. “It was
immediately clear that Bob exceeded our collective criteria for a board member
as he is a seasoned executive with extensive experience growing companies
commercially. His experience managing and growing several hundred million
dollar divisions within Medtronic, and as the current CEO of TYRX, will be
incredibly valuable as we seek to further penetrate the AF market. We are
thrilled to have him on board.”

"I am pleased to be joining AtriCure, a company at its inflection point in
terms of growth and of making great progress in the treatment of atrial
fibrillation," said Mr. White. "I look forward to working with the Board and
the team at AtriCure to help execute on a solid strategy to expand
commercialization and further develop the current and future pipeline."

About AtriCure, Inc.

AtriCure, Inc. is a medical device company providing innovative Atrial
Fibrillation (Afib) solutions designed to produce superior outcomes that
reduce the economic and social burden of Atrial Fibrillation. AtriCure’s
Synergy Ablation System is the first and only device approved for the
treatment of Persistent and Longstanding Persistent forms of Afib in patients
undergoing certain open concomitant procedures. AtriCure’s AtriClip Left
Atrial Appendage (LAA) exclusion device is the most widely implanted device
for LAA management worldwide.The company believes cardiothoracic surgeons are
adopting its ablation and LAA management devices for the treatment of Afib and
reduction of Afib related complications such as stroke. Afib affects more than
5.5 million people worldwide.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements that address activities, events or developments
that AtriCure expects, believes or anticipates will or may occur in the
future, such as earnings estimates (including projections and guidance), other
predictions of financial performance, launches by AtriCure of new products and
market acceptance of AtriCure’s products. Forward-looking statements are based
on AtriCure’s experience and perception of current conditions, trends,
expected future developments and other factors it believes are appropriate
under the circumstances and are subject to numerous risks and uncertainties,
many of which are beyond AtriCure’s control. These risks and uncertainties
include the rate and degree of market acceptance of AtriCure’s products,
AtriCure’s ability to develop and market new and enhanced products, the timing
of and ability to obtain and maintain regulatory clearances and approvals for
its products, the timing of and ability to obtain reimbursement of procedures
utilizing AtriCure’s products, competition from existing and new products and
procedures or AtriCure’s ability to effectively react to other risks and
uncertainties described from time to time in AtriCure’s SEC filings, such as
fluctuation of quarterly financial results, reliance on third party
manufacturers and suppliers, litigation or other proceedings, government
regulation and stock price volatility. AtriCure does not guarantee any
forward-looking statement, and actual results may differ materially from those
projected. AtriCure undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information, future
events or otherwise. A further list and description of risks, uncertainties
and other matters can be found in our Annual Reports on Form 10-K and
Quarterly Reports on Form 10-Q.


AtriCure, Inc.
Andy Wade, 513-755-4564
Vice President and Chief Financial Officer
Investor Relations Contact:
Westwicke Partners
Lynn Pieper, 415-202-5678
Press spacebar to pause and continue. Press esc to stop.